Overview

SHR-A1811 Combined With Bevacizumab in HER2-positive Breast Cancer With Brain Metastases

Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This study aimed to evaluate the use of SHR-A1811 and bevacizumab in HER2-positive Breast Cancer with brain metastases
Phase:
PHASE2
Details
Lead Sponsor:
Huihua Xiong
Treatments:
Bevacizumab